Improved genetic and risk-factor score to find people at higher risk for pancreatic cancer
Multifactor risk scores with susceptibility gene mutations to enhance risk assessment of pancreatic cancer
This project will create a new risk score that combines inherited gene changes and other risk factors to spot people more likely to develop pancreatic cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11190790 on NIH RePORTER |
What this research studies
If you take part, the team will use genetic sequencing and health information from Mayo Clinic patients and a large UK dataset to build a new risk score that includes inherited cancer-gene mutations alongside other risk factors. They will compare existing models, add pathogenic variants found by whole exome sequencing, and then check the new score in a separate group to see how it performs. The researchers will also test the score in first-degree relatives of pancreatic cancer patients to see if it better identifies people at moderate to high risk. All data come from already-collected patient samples and records processed using the same sequencing and analysis methods.
Who could benefit from this research
Good fit: Ideal candidates would be adults with a family history of pancreatic cancer or those known to carry inherited cancer-predisposing gene mutations, and people connected to the Mayo Clinic Biobank or affected family networks.
Not a fit: People already diagnosed with pancreatic cancer or individuals without a family history or relevant genetic changes may not get direct benefit from this risk-scoring work.
Why it matters
Potential benefit: If successful, this could help identify people at higher risk for pancreatic cancer earlier so they can consider closer monitoring or preventive steps.
How similar studies have performed: Related risk scores using common genetic variants and lifestyle factors have shown promise for cancer risk prediction, but adding inherited cancer-syndrome mutations to pancreatic cancer scores is a new approach.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Oberg, Ann Laura — Mayo Clinic Rochester
- Study coordinator: Oberg, Ann Laura
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.